LncPRESS1 promotes the progression and cisplatin resistance of breast cancer through upregulation of ENO1 and activation of glycolysis
In summary, we demonstrated that LncPRESS1 facilitated BRCA progression and cisplatin resistance via activation of ENO1-mediated glycolysis. Combination of ENO1 inhibitor and cisplatin was a promising therapeutic stragtegy for BRCA patients with overexpression of LncPRESS1.
Authors
- Wei Gao (ORCID: https://orcid.org/0000-0002-7889-1662)
- Longzhu Ke
- Yuanxiu Leng
- Yingwen Zhang (ORCID: https://orcid.org/0000-0002-7777-3234)
- Shangshang Li
- Li Luo (ORCID: https://orcid.org/0000-0002-0536-0481)
- Jie Chen (ORCID: https://orcid.org/0000-0003-2752-2098)
- Hong Chen (ORCID: https://orcid.org/0000-0003-0921-2547)
Institutions
- Guiyang College of Traditional Chinese Medicine (CN)
- Tongji University (CN)
- Hubei University of Chinese Medicine (CN)
- Wuhan University (CN)
- Guiyang University (CN)
- Zhongnan Hospital of Wuhan University (CN)
- The First People's Hospital of Guiyang (CN)
Publication Details
- Journal
- Cell Division
- Published
- 2025-10-04
- DOI
- https://doi.org/10.1186/s13008-025-00167-9
- Primary Topic
- RNA modifications and cancer
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Tongji University